SGI-1027 and the Next Era of Cancer Epigenetics: Mechanis...

2026-01-20

This thought-leadership article dissects the dual mechanistic action of SGI-1027, a potent quinoline-based DNA methyltransferase inhibitor, and provides translational researchers with advanced guidance for workflow optimization and therapeutic discovery. Anchored in recent in vitro evaluation paradigms and comparative insights, we contextualize SGI-1027’s unique capabilities—including CpG island demethylation, tumor suppressor gene reactivation, and DNMT1 degradation—within the evolving cancer epigenetics landscape.